van Asselt, Antoinette D. I. http://orcid.org/0000-0001-7705-9906
Armstrong, Nigel
Kimman, Merel
Peeters, Andrea
McDermott, Kevin
Stirk, Lisa
Ahmadu, Charlotte
Govers, Tim M.
Hoentjen, Frank
Joore, Manuela A.
Grimm, Sabine E.
Funding for this research was provided by:
Health Technology Assessment Programme
Article History
Accepted: 12 January 2023
First Online: 1 February 2023
Declarations
:
: This project was funded by the National Institute for Health Research Health Technology Assessment Programme. Please visit the Health Technology Assessment programme website for further project information (ExternalRef removed).
: Antoinette D.I. van Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim Govers, Frank Hoentjen, Manuela A. Joore, and Sabine E. Grimm have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The data used and generated during the current study is not publicly available other than what is published by NICE on their website at ExternalRef removed. The reason for the confidentiality is that all information in the reimbursement dossiers sent to NICE by pharmceutical companies is reserved except for data already available from public sources and data not marked as confidential by the companies.
: Not applicable.
: All authors have commented on the submitted manuscript and have given their approval for the final version to be published. NA, KMD and CA critiqued the clinical effectiveness data reported by the company. LS critiqued the literature searches undertaken by the company. FH provided clinical expert opinion on loss of response and treatment sequences. AvA, NA, MK, AP, TG, MJ and SG critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. AvA acts as the overall guarantor for the article. This article has not been externally peer reviewed by <i>Pharmacoeconomics</i>.